Morningstar
Get 14 Days Free

AXA Framlington Biotech Fund GBP Z Acc

Performance History31/07/2020
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech Fund GBP Z Acc
Fund-4.99.7-6.419.422.2
+/-Cat-1.0-0.61.5-0.86.2
+/-B’mrk1.2-1.4-3.2-0.99.2
 
Category: Sector Equity Biotechnology
Category Benchmark: NASDAQ Biotechnology TR USD
Key Stats
NAV
06/08/2020		 GBX 435.60
Day Change -0.64%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB00B784NS11
Fund Size (Mil)
30/06/2020		 GBP 513.28
Share Class Size (Mil)
06/08/2020		 GBP 335.76
Max Initial Charge -
Ongoing Charge
07/08/2019		  0.83%
Investment Objective: AXA Framlington Biotech Fund GBP Z Acc
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.
Returns
Trailing Returns (GBP)06/08/2020
YTD22.64
3 Years Annualised11.04
5 Years Annualised4.90
10 Years Annualised*19.41
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
16/04/2012
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech Fund GBP Z Acc30/06/2020
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.300.0095.30
Bond0.000.000.00
Property0.000.000.00
Cash4.030.333.70
Other1.000.001.00
Top 5 Regions%
United States89.74
Eurozone4.15
Asia - Emerging2.79
Europe - ex Euro2.35
United Kingdom0.96
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare7.93
Amgen IncHealthcareHealthcare6.94
Biogen IncHealthcareHealthcare5.47
Alexion Pharmaceuticals IncHealthcareHealthcare4.75
Vertex Pharmaceuticals IncHealthcareHealthcare4.65
Increase Decrease New since last portfolio
AXA Framlington Biotech Fund GBP Z Acc

Related

Fund Research & Insights
Best Performing Funds Since the Global Recession
A decade on from the beginning of the credit crisis, which fund managers have emerged the winners? One sector dominates the best performers
Emma Wall
Investing for Retirement
Investor Views: "Should I Cash in my £850,000 Pension?"
Private investor Andrew Knight fears falling foul of lifetime pension contribution limits if he accesses a scheme from a previous employer
Emma Simon
Fund Research & Insights
Investors Back Global Funds and Star Managers in May
World stocks hit record high last week. Reflecting these global gains the top 10 most clicked funds on Morningstar.co.uk last month are a varied ...
Karen Kwok
Fund Research & Insights
ISA and SIPP Investors' Favourite Funds
Where are investors allocating their ISA and SIPP allowances? There is just one day to go until the end of the 2016/17 tax year
Karen Kwok
Fund Research & Insights
Investors Pin Hopes on Commodity Funds in January
Given the rally in commodity prices last, it is not surprising that funds in this sector were among the popular with Morningstar investors last month
Karen Kwok
Fund Research & Insights
Investors Pick India as Top Spot for Growth
An India equity fund has joined the most popular list as voted for by Morningstar.co.uk readers. We hear from the professionals why the Indian stock m...
Karen Kwok
Fund Research & Insights
UK Equity Income Funds Remain Popular Amid Brexit Fallout
With the FTSE 100 reaching record levels, high-conviction equity income funds remain popular among Morningstar.co.uk readers in September
Karen Kwok
Fund Research & Insights
Woodford Equity Income Breaks £9bn Barrier Despite Outflows
Woodford Equity Income swells to £9.2 billion under management despite outflows, as IA reports industry assets at 12 month high despite Brexit s...
Karen Kwok
Fund Research & Insights
Fund Managers Attempt to Thwart EU Ban on Past Performance Data
Asset managers urge European Union Commission to ditch proposed changes to retail fund rules
Emma Simon
Fund Research & Insights
Top 5 Funds on Morningstar
Which are the most popular funds according to Morningstar readers? Our top 5 list shows a bias towards home-grown stocks, and healthcare funds
Karen Kwok
* This share class has performance data calculated prior to the inception date, 2012-04-16. This is based upon a simulated/extended track record, using the track record of AXA Framlington Biotech R Acc (ISIN: GB0031007254), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.
  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.      Terms of Use     Privacy Policy.    Cookie Consent
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies

The Morningstar Star Rating for Stocks is assigned based on an analyst's estimate of a stocks fair value. It is projection/opinion and not a statement of fact. Morningstar assigns star ratings based on an analyst’s estimate of a stock's fair value. Four components drive the Star Rating: (1) our assessment of the firm’s economic moat, (2) our estimate of the stock’s fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process culminates in a single-point star rating that is updated daily. A 5-star represents a belief that the stock is a good value at its current price; a 1-star stock isn't. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Morningstar Star Rating for Stocks, please visit here

Quantitative Fair Value Estimate represents Morningstar’s estimate of the per share dollar amount that a company’s equity is worth today. The Quantitative Fair Value Estimate is based on a statistical model derived from the Fair Value Estimate Morningstar’s equity analysts assign to companies which includes a financial forecast of the company. The Quantitative Fair Value Estimate is calculated daily. It is a projection/opinion and not a statement of fact. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Quantiative Fair Value Estimate, please visit here